Iason GmbH has continued its refinancing efforts with local banks based on an IBR
The shareholders of Iason GmbH have completed a restructuring of the company and its refinancing efforts with local banks based on an IBR.
The Iason group produces radiopharmaceuticals and supplies special laboratory products to the target group "nuclear medicine" and "laboratory medicine" providing innovative products with the highest quality standards. The company has customers from all over Europe.
Oaklins' team in Austria assisted Iason with the preparation of the IBR (independent business review) and negotiations with local banks regarding refinancing possibilities.
Talk to the deal team
Related deals
MBI Healthcare Technologies has been acquired by DNV AS
The founders of MBI Healthcare Technologies have sold the company to DNV AS. The acquisition forms part of DNV’s strategic expansion into the digital health market, where it aims to significantly grow its presence through innovation, acquisitions, and partnerships. DNV and MBI will work to rapidly scale MBI’s solutions in the UK, target growth in international markets and bring new data assurance technologies to the healthcare sector.
Learn moreSulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
Learn moreLaboratoire Dazont has been acquired by SBM Company
The shareholders of Laboratoire Dazont have sold the company to SBM Company.
Learn more